|
Variables
|
Levels
|
Number of cases
|
%
|
5-year survival rate
|
P
|
|---|
|
Age at diagnosis
|
<40
|
126
|
4.51
|
0.9029
|
<0.01
|
| |
40-49
|
1128
|
40.42
|
0.9166
| |
| |
50-59
|
794
|
28.45
|
0.8827
| |
| |
60-69
|
469
|
16.8
|
0.8586
| |
| |
≥70
|
274
|
9.82
|
0.8356
| |
|
Education
|
<Middle School
|
361
|
12.93
|
0.7941
|
<0.01
|
| |
Middle School
|
988
|
35.40
|
0.8948
| |
| |
> Middle School
|
1442
|
51.67
|
0.9096
| |
|
Income
|
<1,000
|
1723
|
61.73
|
0.8696
|
<0.01
|
|
(CNY¥/person/month)
|
1,000 - 1,999
|
777
|
27.84
|
0.9141
| |
| |
≥2,000
|
291
|
10.43
|
0.9415
| |
|
TNM stage
|
0
|
63
|
2.26
|
1.0000
|
<0.01
|
| |
I
|
871
|
31.21
|
0.9545
| |
| |
IIa
|
945
|
33.86
|
0.9221
| |
| |
IIb
|
549
|
19.67
|
0.8174
| |
| |
III-IV
|
272
|
9.75
|
0.6724
| |
|
Histologic grade
|
I
|
438
|
15.69
|
0.9611
|
<0.01
|
| |
II
|
1312
|
47.01
|
0.9002
| |
| |
III
|
803
|
28.77
|
0.8274
| |
| |
Unknown
|
238
|
8.53
|
0.9231
| |
|
Histologic type*
|
Noninvasive (DCIS, LCIS)
|
96
|
3.44
|
1.0000
|
<0.01
|
| |
ILC NOS
|
215
|
7.70
|
0.8797
| |
| |
IDC NOS
|
1924
|
68.94
|
0.8745
| |
| |
Special types
|
527
|
18.88
|
0.9264
| |
| |
Unknown
|
29
|
1.04
|
0.8966
| |
|
ERα
|
Positive (> = 10%)
|
1740
|
62.34
|
0.9206
|
<0.01
|
| |
Negative
|
1051
|
37.66
|
0.8354
| |
|
PR
|
Positive (> = 1%)
|
1632
|
58.47
|
0.9183
|
<0.01
|
| |
Negative
|
1159
|
41.53
|
0.8465
| |
|
HER2
|
Positive (3+)
|
849
|
30.42
|
0.8621
|
0.02
|
| |
Borderline (2+)
|
227
|
8.13
|
0.8768
| |
| |
Negative (0-1+)
|
1715
|
61.45
|
0.9032
| |
|
Molecular subtype**
|
Luminal A
|
1355
|
48.55
|
0.9286
|
<0.01
|
| |
Luminal B
|
467
|
16.73
|
0.8862
| |
| |
HER2
|
382
|
13.69
|
0.8322
| |
| |
Triple negative
|
360
|
12.90
|
0.8069
| |
| |
HER2 borderline
|
227
|
8.13
|
0.8768
| |
|
Radiotherapy
|
Yes
|
874
|
31.31
|
0.8409
|
<0.01
|
| |
No
|
1917
|
68.69
|
0.9098
| |
|
Chemotherapy
|
Yes
|
2558
|
91.65
|
0.8890
|
0.99
|
| |
No
|
233
|
8.35
|
0.8818
| |
|
Immunotherapy
|
Yes
|
477
|
17.09
|
0.9118
|
0.18
|
| |
No
|
2310
|
82.77
|
0.8844
| |
| |
Unknown
|
4
|
0.14
|
0.7500
| |
|
Tamoxifen ***
|
Yes
|
1484
|
53.17
|
0.9123
|
<0.01
|
| |
No
|
1306
|
46.79
|
0.8612
| |
- *DCIS: ductal carcinoma in situ; LCIS: lobular carcinoma in situ; IDC NOS: invasive ductal carcinoma not otherwise specified; ILC NOS: invasive lobular carcinoma not otherwise specified; Special types: including mucinous, papillary, medullary, tubular, cribriform, metaplastic, mixed, and other rare invasive cancers.
- ** Luminal A: ERα+ and/or PR+, HER2-; luminal B: ERα+ and/or PR+, HER2+; HER2: HER2+, ERα-, and PR-; triple negative: ERα-, PR-, HER2-: HER2 borderline: weak staining of HER2 (2+).
- ***One case with unknown tamoxifen use was excluded.
